top of page

CHO-K1/Rat CT Stable Cell

Item
Cat#
Price

Stable Cell Line

SNB-G-0040C

$19,800

Compound Testing Services

CT-001

$1,850 per 384w plate

(Up To 16 cpds Dose)


Product Description


The Calcitonin Receptor (CTR or CALCR) is a G protein-coupled receptor activated by the hormone calcitonin. It is highly expressed on osteoclasts and also found in the kidneys, central nervous system, and some cancer cells. Its primary function is to mediate calcitonin's effects on bone and mineral metabolism, including potently inhibiting osteoclast-mediated bone resorption, regulating renal calcium and phosphate excretion, and potentially modulating pain perception in the CNS. Consequently, the calcitonin receptor is the direct target for drugs treating osteoporosis and Paget's disease of bone, with its analogs (e.g., salmon calcitonin) being widely used clinically.

 

Screeningbio’s CHO-K1/Rat CT cell line overexpress CALCR and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.

Product Specifications

Target Type

GPCR

Species

Rat

HGNC Symbol

CALCR

Accession Number

NM_001034015

Parental Line

CHO-K1

Lot#

See Vial

Storage

Liquid Nitrogen


Data


CHO-K1/Rat CT Agonist Assay. CHO-K1/Rat CT cells were treated with the reference agonist. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.
CHO-K1/Rat CT Agonist Assay. CHO-K1/Rat CT cells were treated with the reference agonist. The assay was run based on Revvity cAMP HTRF protocol. Non-linear regression was used to plot activity changes vs. [Compound, M], and EC50 values were determined, using GraphPad Prism software.


Target Background


The Calcitonin Receptor (CTR or CALCR) is a G protein-coupled receptor activated by the hormone calcitonin. It is highly expressed on osteoclasts and also found in the kidneys, central nervous system, and some cancer cells.


Its primary function is to mediate calcitonin's effects on bone and mineral metabolism, including potently inhibiting osteoclast-mediated bone resorption, regulating renal calcium and phosphate excretion, and potentially modulating pain perception in the CNS.


Consequently, the calcitonin receptor is the direct target for drugs treating osteoporosis and Paget's disease of bone, with its analogs (e.g., salmon calcitonin) being widely used clinically.


 



Product Documentation



bottom of page